Newsmeme!
Discover News you didn't know existed
Hyperion Therapeutics announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the pivotal Phase III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea cycle disorders (UCD).
SOUTH SAN FRANCISCO, Calif.----Hyperion Therapeutics today announced that it has reached agreement with the U.S. Food and Drug Administration under the Special Protocol Assessment process for the pivotal Phase III trial of investigational product HPN-100 in adults with urea cycle disorders .
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |